Two lines of investigation have focussed interest on dopaminergic mechanisms in schizophrenia, observations on amphetamine psychosis and research on the mechanism of the antipsychotic effect of neuroleptic drugs. From this work has arisen the concept that neuroleptic drugs exert their therapeutic effects by blocking central dopamine receptors. It has also been suggested that in schizophrenia there may be excessive or inappropriate activity of dopamine neurones.
Amphetamine Psychosis
Many of the most characteristic features of schizophrenia are seen in psychoses observed in patients who abuse amphetamines (Connell 1958 , Ellinwood 1967 ) and can also be induced in experimental subjects (Angrist et al. 1974b ). Since psychotic changes can be provoked in most (if not all) subjects if sufficiently large doses are administered, it seems unlikely that the psychosis. is an idiosyncratic response (Griffith et al. 1972) . Such changes can also occur within 24 h of the first dose (Griffith et a. 1972 , Angrist et al. 1974b and it seems unlikely therefore that they are a secondary consequence of sleep deprivation. It must be concluded that these changes are almost certainly a direct pharmacological consequence of drug administration. Randrup & Munkvad (1966 , 1967 demonstrated that several of the behavioural effects of amphetamines are dependent upon the integrity of central dopamine stores and these effects are selectively antagonized by neuroleptic drugs (Randrup & Munkvad 1965) . Evidence that the psychological changes in amphetamine psychosis in man are similarly dependent upon increased dopamine release is more difficult to obtain. CSF studies suggest that dopamine turnover is increased following psychotogenic doses of amphetamine (Angrist et al. 1974b ) and the psychological changes of amphetamine psychosis are diminished by drugs with dopamine receptor blocking activities (Gunne et al. 1972 , Angrist etal. 1974a ).
Neuroleptics and Dopamine Blockade
According to Horn & Snyder (1971) the threedimensional structure of chlorpromazine bears a Dr T J Crow relationship to that of dopamine, since the dimethylaminopropyl side chain is able to assume a position'which can accommodate the ethylamine chain of the dopamine molecule. This conformation is dependent upon the presence of the chlorine substituent on the third ring of the chlorpromazine molecule. The chlorine atom is absent in promazine and it is well established that promazine, while it possesses some antipsychotic activity, is much less potent than chlorpromazine (Casey et al. 1960) . Promazine is also a less potent inhibitor of the dopamine sensitive adeylate cyclase in the corpus striatum (Miller etal. 1974 ).
Thus, small changes in molecular structure can substantially influence the antipsychotic effect. Because the side chain of the thiaxanthenes is attached to the ring structure by a carbon-carbon double bond, this group of compounds exhibits a geometrical isomerism. This isomerism has been shown to be highly relevant to the dopamine receptor blocking potencies of this group of drugs .
A particularly interesting case is that of flupenthixol, since the standard oral preparation which is widely used in clinical practice is a racemic mixture of both isomers and it has been demonstrated by in vitro tests ) that the cis-(or a) isomer is more than 1000 times more potent than the trans-(org) isomer. For this reason a clinical trial of the relative therapeutic efficacies of these two isomers was of particular importance. The dopamine blockade hypothesis clearly predicts that all the antipsychotic effect should be associated with a-isomer. If the ,8isomer could be shown to be equally active, this would eliminate the hypothesis. Even if it were shown to have significantly more activity than 1S placebo, this would suggest that actions other than dopamine receptor blockade are relevant to the antipsychotic effect. Thus the isomers of flupenthixol can be used as a tool for investigating the role of dopaminergic processes in schizophrenia.
In a double-blind controlled trial, the two isomers were compared with placebo in a study of 45 recently admitted patients with a first episode or exacerbation of a schizophrenic psychosis , Crow et al. 1977b . Schizophrenia was diagnosed by Present State Examination criteria and patients were allocated at random to treatment with a-or fl-flupenthixol or placebo, with 15 patients in each group. The dose administered was 6 mg for the first week and 9 mg for the remaining 3 weeks of the trial. All patients were given anti-Parkinsonian medication (orphenadrine, 50 mg thrice daily) and additional doses of chlorpromazine, where further medication was considered imperative, were treated as a second dependent variable. Clinical state was rated by standardized interview at weekly intervals.
The major finding of the trial (Fig 1) was that, although there were substantial improvements in patients on placebo, patients on a-flupenthixol had improved to a significantly (P<0.05) greater extent at the third and fourth weeks than patients on either ,8-flupenthixol or placebo. Patients on ,B-flupenthixol did slightly, but not significantly, worse than those on placebo. The findings (which were similar whether analyzed as above or in terms of additional chlorpromazine) are therefore consistent with the hypothesis that dopamine receptor blockade is the sole mechanism of the antipsychotic effect.
Since there are several pharmacological actions (e.g. noradrenaline, acetylcholine and opiate receptor blockade) in which the two isomers are approximately equally potent, these actions can probably be ruled out as the mechanism of the therapeutic effect (Johnstone et al. 1977, submitted) . However, the a-isomer is probably substantially more potent than the ,B-isomer in blocking the serotonin receptor (Enna et al. 1976) and serotonin receptor blockade cannot be excluded, although it seems unlikely as the mechanism of the therapeutic effect since there is a very poor relationship between ability to interact with the serotonin receptor and therapeutic potency (Bennett & Snyder 1975) . Therefore dopamine receptor blockade remains the sole known pharmacological effect which can account for the effectiveness of a wide variety of neuroleptic drugs.
Dopamine Receptor Blockade and Types of Schizophrenic Illness
The flupenthixol isomers as a pharmacological tool can also be used to investigate the question of which type of schizphrenic illness is most influenced by the drug effect. Although trial patients were selected on the basis of Present State Examination criteria, alternative criteria can be applied. For example, it is possible to select out a group of patients with additional affective disturbances sufficient to qualify for a diagnosis of affective disorder (schizoaffective patients) and to contrast these patients with those without such disturbance (non-schizoaffective patients). The patient group can also be subdivided on the basis of the Feighner criteria for schizophrenia, for which evidence of chronicity is required. The extent of the drug effect (calculated as improvement on a-flupenthixol minus mean improvement on the f-isomer and placebo) was estimated in each of these groups (Fig 2) . It was found to be greater in non-schizoaffective patients and negligible in the schizoaffective group and greater in Feighner positive than Feighner negative patients.
Thus, in either case, the antipsychotic effect appears to be greater in the more typically schizophrenic patients.
Dopamine Receptor Blockade and Types of Schizophrenic Symptom
Analysis of individual symptomratings revealed that there were no differences between treatments with respect to non-schizophrenic symptoms (anxiety, depression and retardation). On typically schizophrenic symptoms it was apparent that patients on a-flupenthixol showed greater improvements in each of those symptoms (hallucinations, delusions, incoherence of speech and incongruity of affect) which had been classified Schizophrenia attributable to blockade of the inhibitory effect of the tubero-infundibular dopamine system on prolactin secretion (Fuxe et al. 1969) . Increased prolactin secretion was seen on a-but not on ,8-flupenthixol (Cotes et al. 1977) . A comparison of the time course of the prolactin increase with that of the therapeutic effect (calculated as the difference between ratings of patients on ,flupenthixol and placebo) revealed that there is a substantial discrepancy between the two. The prolactin increase appears well established at the end of the first week, but the greatest therapeutic improvement due to drugs takes place between weeks two and three (Fig 4) . Thus there is a delay of at least two weeks between the onset of dopamine receptor blockade, as indicated by the prolactin increase and the antipsychotic effect. This suggests that dopamine receptor blockade, if necessary for the therapeutic effect, is required to allow some other and longerterm process to take place and it is this process rather than dopamine receptor blockade itself which is responsible for the change in symptoms. This observation alone perhaps casts doubt upon the interpretation of the antipsychotic effect as a simple reversal of a neurohumoural imbalance affecting primarily dopaminergic neurones.
The Site ofthe Antipsychotic Effect It has long been recognized that the extrapyramidal effects of neuroleptic drugs are not directly related to the therapeutic effect (National Institute of Mental Health -PSC 1964). Therefore if both are due to dopaminergic blockade, it seems likely that they are taking place at different sites within the CNS. It has recently been demonstrated (Crow et al. 1977a ) that for the three drugs thioridazine, chlorpromazine and fluphenazine (which differ widely in incidence ofextrapyramidal effects) the antipsychotic potency is better correlated with actions on the mesolimbic speech) there were no differences between the three treatments, (Fig 3) . Thus it appears that dopaminergic blockade may improve only a subset of symptoms of the disease and may not affect those features which contribute so substantially to the morbidity of the schizophrenic defect state. It should be noted that such features were present only in a minority of patients in the trial and when present (by contrast with the positive symptoms) these symptoms showed little tendency to improve, irrespective of treatment.
Time Course ofthe Antipsychotic Effect
Prolactin secretion increases in patients on neuroleptic drugs, an effect which is presumably 17 ol-dopamine system (in particular in the nucleus accumbens) than on the nigrostriatal system. Extrapyramidal effects were better correlated with actions on the latter system.
A plausible explanation for the differing actions of various drugs on the two areas is that the drugs with a lesser incidence of Parkinsonian effects (e.g. thioridazine) are those with high antimuscarinic activity (Miller & Hiley 1974) . Since anticholinergic drugs exert therapeutic effects in Parkinsonism, thioridazine and similar compounds may possess 'in-built' anti-Parkinsonian activity. It seems likely that there are cholinergic-dopaminergic interactions in the striatum which are absent in the nucleus accumbens. The findings do not exclude a site of antipsychotic effect elsewhere within the mesolimbic system (e.g. in the frontal cortex) but an action in the nucleus accumbens seems entirely possible. The interesting anatomical relationships between the nucleus accumbens and hippocampus (Swanson & Cowan 1975) may provoke further discussion of the possible role of this limbic structure in the pathogenesis of schizophrenia.
Is There Excess Dopamine Release in Schizophrenia ?
There are a number of reasons for doubting that a simple excess of dopamine release occurs in the majority of schizophrenic illnesses.
(1) There is no decrease in prolactin secretion in unmedicated acute (Meltzer et al. 1974) or chronic patients, such as might be expected if excess dopamine release were generalized and affected the tubero-infundibular as well as other central dopamine systems.
(2) Attempts to demonstrate increased dopamine turnover using the probenecid technique (Bowers 1974 , Post et al. 1975 ) have failed, although this technique appears to be adequate to demonstrate such a change in the case of amphetamine psychosis (Angrist et al. 1974b ).
(3) The pridr presence ofa Parkinsonian syndrome does not preclude the subsequent development of a psychotic illness with schizophrenia-like symptoms (Crow et al. 1976) . Since it has been demonstrated (Farley et al. 1977 ) that dopamine is as depleted in the mesolimbic as in the striatal system in Parkinson's disease, these findings suggest that increased dopamine release is at least not necessary for the emergence of schizophrenic symptoms.
Finally, it has recently been possible to assay dopamine and its major metabolite, homovanillic acid (HVA), in brains collected at post-mortem from 10 patients who in life had suffered from schizophrenic illnesses and 10 age-matched control subjects dying from a variety of physical illnesses. The findings (Table 1) significant increase in the dopamine metabolite either in accumbens or putamen and no change in glutamic acid decarboxylase, the synthetic enzyme for the inhibitory transmitter GABA. This suggests that there is no gross disturbance of dopamine or GABA neurones in schizophrenia. However, the relationships between the two transmitters may be changed. In control brains, in both putamen and accumbens there was a positive correlation between GAD and HVA (Table 2) . In schizophrenic brains, this relationship was present in putamen but absent in accumbens.
Thus, there is a possibility that there may be a subtle disturbance of the relationship between dopamine and GABA neurones in schizophrenia, although it is also possible that this is an effect of neuroleptic drugs. Table 2 Correlation of GAD and HVA in normal and schizophrenic brains 
Conclusions
The dopamine blockade hypothesis of the antipsychotic effect has survived a stringent clinical test and some alternative pharmacological actions can be ruled out. The antipsychotic effect is greater in more typically schizophrenic illnesses (defined by absence of affective symptoms or presence of chronicity). It also affects typically schizophrenic features, but may be limited to the positive symptoms of the disease. The time course of the clinical change attributable to medication is delayed by at least two weeks from the onset of dopamine receptor blockade, as indicated by increased prolactin secretion. This suggests that the therapeutic effect may be a somewhat indirect consequence of dopamine receptor blockade.
There is little evidence for excessive dopamine release as the primary pathogenic process in schizophrenia. Studies of prolactin secretion, as an index oftubero-infundibular dopamine activity, and of homovanillic acid in CSF have revealed no evidence of increased dopamine release and postmortem studies show homovanillic acid concentrations in brain to be similar in schizophrenics and controls. Thus it seems likely that the primary disturbance in schizophrenia does not lie in the dopamine neurone. It remains possible that there may be an abnormal responsiveness to dopamine of the postsynaptic receptor or of neural elements beyond this, or that there may be an abnormality of a neural system which interacts in some way with the mesolimbic dopamine pathway.
